Founded in 2011, XenoGesis now has clients across six continents and has experienced consistent growth since day one, with export revenue increasing year-on-year. The increase in international clients is the direct result of the business’ growth strategy to develop overseas markets.
Based at BioCity Nottingham, XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology, DMPK due diligence and modelling and simulation, and has worked directly on the predictions of human PK and dose for eight compounds that have entered clinic.
In the financial year ending March 2019, 50% (£1.25 million) of all its revenue came from overseas clients, with its largest markets being in Europe, representing a 78% increase on the previous year. A trend that has continued.
Commenting, Richard Weaver, Founder and CEO of XenoGesis, said: “We are honoured to receive the Queen’s Award for Enterprise. This is testament to the team’s hard work and our focus on international growth. The UK’s wealth of scientific knowledge and expertise highlights the attractive proposition this country has to offer, and over recent years we have seen a marked increase in international businesses turning to us, and other UK CROs, for expertise, advice and support.
“This is bittersweet timing for us, following the loss of one of our much-loved and highly-experienced colleagues who sadly passed away this month. As a founding member of XenoGesis, he would have been proud of this achievement and the integral role he played in helping grow the business. This award is received in his memory.”
He added: “We expect the growth trend to continue with more and more clients coming to us from overseas for our high quality, consultative and flexible approach.”
The Queen’s Awards for Enterprise are the most prestigious awards for UK businesses, recognising and celebrating business excellence across the UK. XenoGesis is one of 220 organisations nationally to be recognised this year with a Queen’s Award for Enterprise.
XenoGesis will receive the award from the Lord Lieutenant at a date to be announced, and representatives from the company will attend a Royal reception later this year.